Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (22441)	6/17/1998 11:40:00 PM
From: bob zagorin	Respond to of 32384

Ligand Pharmaceuticals Inc. (LGND): The drugmaker and its partner Seragen Inc. (SRGN) said the U.S. Food and Drug Administration found deficiencies in the company's application to sell its Ontak drug and won't approve it for use in treating patients with a rare cancer at this time. Ligand was unchanged at 13 1/2. Seragen fell .03 to .57. Bloomberg

To: celeryroot.com who wrote (22441)	6/18/1998 2:29:00 AM
From: Torben Noerup Nielsen	Respond to of 32384

Off Topic... >Welcome back. how was your trip Tokyo was ok. Europe wasn't too bad. Copenhagen was kind of cold, but that is normal. Tromso (Norway) was cold and cloudy; the mountains were still snow covered and the leaves were only just appearing on the trees. And it is hard to sleep when the sun never sets! Also, I had to get out of there in a hurry - on a 4 am flight - due to a looming ATC strike. After that I spent a couple of days in London and that was quite pleasant. And then I came home to find that my portfolio had gone on a diet of sorts; way down :-( Oh well, c'est la vie. Cheers, Torben